
    
      In this double-blind, placebo-controlled, phase Ib study, 128 patients with active RA are
      planned to be enrolled and randomly assigned 1:1:1:1 to receive placebo, or different doses
      of GCK tablet (100/200/300 mg). This study will evaluate the safety, pharmacokinetics and
      preliminary efficacy of GCK tablets in patients with rheumatoid arthritis
    
  